|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Enzinger PC and Mayer RJ: Esophageal
cancer. N Engl J Med. 349:2241–2252. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Abnet CC, Arnold M and Wei WQ:
Epidemiology of esophageal squamous cell carcinoma.
Gastroenterology. 154:360–373. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Baba Y, Saeki H, Nakashima Y, Oki E,
Shigaki H, Yoshida N, Watanabe M, Maehara Y and Baba H: Review of
chemotherapeutic approaches for operable and inoperable esophageal
squamous cell carcinoma. Dis Esophagus. 30:1–7. 2017.
|
|
5
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mei LL, Qiu YT, Zhang B and Shi ZZ:
MicroRNAs in esophageal squamous cell carcinoma: Potential
biomarkers and therapeutic targets. Cancer Biomark. 19:1–9. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Harada K, Baba Y, Ishimoto T, Shigaki H,
Kosumi K, Yoshida N, Watanabe M and Baba H: The role of microRNA in
esophageal squamous cell carcinoma. J Gastroenterol. 51:520–530.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen M, Liu YY, Zheng MQ, Wang XL, Gao XH,
Chen L and Zhang GM: microRNA-544 promoted human osteosarcoma cell
proliferation by downregulating AXIN2 expression. Oncol Lett.
15:7076–7082. 2018.PubMed/NCBI
|
|
9
|
Pan C, Xiang L, Pan Z, Wang X, Li J, Zhuge
L, Fang P, Xie Q and Hu X: MiR-544 promotes immune escape through
downregulation of NCR1/NKp46 via targeting RUNX3 in liver cancer.
Cancer Cell Int. 18:522018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yao GD, Zhang YF, Chen P and Ren XB:
MicroRNA-544 promotes colorectal cancer progression by targeting
forkhead box O1. Oncol Lett. 15:991–997. 2018.PubMed/NCBI
|
|
11
|
Zhi Q, Guo X, Guo L, Zhang R, Jiang J, Ji
J, Zhang J, Zhang J, Chen X, Cai Q, et al: Oncogenic miR-544 is an
important molecular target in gastric cancer. Anticancer Agents Med
Chem. 13:270–275. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhu Z, Wang S, Zhu J, Yang Q, Dong H and
Huang J: MicroRNA-544 down-regulates both Bcl6 and Stat3 to inhibit
tumor growth of human triple negative breast cancer. Biol Chem.
397:1087–1095. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jin S, Dai Y, Li C, Fang X, Han H and Wang
D: MicroRNA-544 inhibits glioma proliferation, invasion and
migration but induces cell apoptosis by targeting PARK7. Am J
Transl Res. 8:1826–1837. 2016.PubMed/NCBI
|
|
14
|
Sobin LH, Gospodarowicz MK and Wittekind
C: International union against cancer (UICC) TNM classification of
malignant tumoursWiley-Liss; New York: pp. 73–76. 2010
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fang R, Zhao NN, Zeng KX, Wen Q, Xiao P,
Luo X, Liu XW and Wang YL: MicroRNA-544 inhibits inflammatory
response and cell apoptosis after cerebral ischemia reperfusion by
targeting IRAK4. Eur Rev Med Pharmacol Sci. 22:5605–5613.
2018.PubMed/NCBI
|
|
17
|
Ren B, Cam H, Takahashi Y, Volkert T,
Terragni J, Young RA and Dynlacht BD: E2F integrates cell cycle
progression with DNA repair, replication and G(2)/M checkpoints.
Genes Dev. 16:245–256. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kothandaraman N, Bajic VB, Brendan PN,
Huak CY, Keow PB, Razvi K, Salto-Tellez M and Choolani M: E2F5
status significantly improves malignancy diagnosis of epithelial
ovarian cancer. BMC Cancer. 10:642010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ishimoto T, Shiozaki A, Ichikawa D,
Fujiwara H, Konishi H, Komatsu S, Kubota T, Okamoto K, Nakashima S,
Shimizu H, et al: E2F5 as an independent prognostic factor in
esophageal squamous cell carcinoma. Anticancer Res. 33:5415–5420.
2013.PubMed/NCBI
|
|
20
|
Zhao J, Wu XY, Ling XH, Lin ZY, Fu X, Deng
YH, He HC and Zhong W: Analysis of genetic aberrations on
chromosomal region 8q21-24 identifies E2F5 as an oncogene with copy
number gain in prostate cancer. Med Oncol. 30:4652013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jiang Y, Yim SH, Xu HD, Jung SH, Yang SY,
Hu HJ, Jung CK and Chung YJ: A potential oncogenic role of the
commonly observed E2F5 overexpression in hepatocellular carcinoma.
World J Gastroenterol. 17:470–477. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lin C, Hu Z, Yuan G, Su H, Zeng Y, Guo Z,
Zhong F, Jiang K and He S: MicroRNA-1179 inhibits the
proliferation, migration and invasion of human pancreatic cancer
cells by targeting E2F5. Chem Biol Interact. 291:65–71. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li L, Wu C and Zhao Y: miRNA-34a enhances
the sensitivity of gastric cancer cells to treatment with
paclitaxel by targeting E2F5. Oncol Lett. 13:4837–4842. 2017.
View Article : Google Scholar : PubMed/NCBI
|
